United Therapeutics (UTH) Ownership - Who Owns United Therapeutics?
United Therapeutics (UTH) Ownership Overview
- 1.95% Insiders
- 21.38% Mutual Funds
- 3.61% Other Institutional Investors
- 31.75% ETFs
- 41.31% Public Companies and Individual Investors
The ownership structure of United Therapeutics (DE:UTH) stock is a mix of institutional, retail, and individual investors. Approximately 56.74% of the company’s stock is owned by Institutional Investors, 1.95% is owned by Insiders, and 41.31% is owned by Public Companies and Individual Investors.
The ownership structure of United Therapeutics (DE:UTH) stock is a mix of institutional, retail, and individual investors. Approximately 56.74% of the company’s stock is owned by Institutional Investors, 1.95% is owned by Insiders, and 41.31% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| May 12, 2026 | Nilda Mesa | $150,138 | |
| Apr 15, 2026 | Martine Rothblatt | $40,271 | |
| Mar 25, 2026 | Tommy Thompson | $1,078,321 | |
| Mar 04, 2026 | Ray Kurzweil | $2,401,088 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Woodline Partners Lp | €382,491 | |
| Dec 31, 2025 | Morningstar Investment Management Llc | €1,698,066 | |
| Dec 31, 2025 | Brandes Investment Partners Lp | €1,970,439 | |
| Dec 31, 2025 | Fisher Asset Management Llc | €14,304,198 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Ishares | 5,109,227 | Institution | 11.91% | 3,077,885,202 |
| Vanguard | 3,727,295 | Institution | 8.69% | 2,245,385,872 |
| Vanguard Index Funds | 3,396,851 | Institution | 7.92% | 2,046,320,789 |
| Spdr | 1,229,885 | Institution | 2.87% | 740,903,632 |
| Invesco | 797,071 | Institution | 1.86% | 480,169,121 |
| Vanguard Specialized Funds | 719,385 | Institution | 1.68% | 433,369,754 |
| Martine Rothblatt | 668,728 | Insider | 1.56% | 402,853,116 |
| Capitol Series Trust | 611,203 | Institution | 1.43% | 368,199,078 |
| Amundi | 520,395 | Institution | 1.21% | 313,494,795 |
| Fidelity Concord Street Trust | 493,788 | Institution | 1.15% | 297,466,286 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 3,396,851 | Institution | 7.92% | 2,046,320,789 |
| Vanguard Specialized Funds | 719,385 | Institution | 1.68% | 433,369,754 |
| Capitol Series Trust | 611,203 | Institution | 1.43% | 368,199,078 |
| Fidelity Concord Street Trust | 493,788 | Institution | 1.15% | 297,466,286 |
| Vanguard World Fund | 385,919 | Institution | 0.90% | 232,484,166 |
| Fidelity Salem Street Trust | 354,770 | Institution | 0.83% | 213,719,479 |
| Tiaa-cref Funds | 314,489 | Institution | 0.73% | 189,453,520 |
| Franklin Custodian Funds | 225,000 | Institution | 0.52% | 135,543,825 |
| Janus Investment Fund | 201,764 | Institution | 0.47% | 121,546,064 |
| Fidelity Commonwealth Trust Ii | 133,842 | Institution | 0.31% | 80,628,696 |
FAQ
Who Owns United Therapeutics (DE:UTH)?
According to the latest TipRanks data, approximately 56.74% of the company's stock is held by institutional investors, 1.95% is held by insiders, and 41.31% is held by public companies and individual investors.
What percentage of United Therapeutics (DE:UTH) stock is held by institutional investors?
According to the latest TipRanks data, approximately 56.74% of United Therapeutics (DE:UTH) stock is held by institutional investors: 21.38% by mutual funds, 31.75% by ETFs and 3.61% by other institutional investors.
What percentage of United Therapeutics (DE:UTH) stock is held by retail investors?
According to the latest TipRanks data, approximately 41.31% of United Therapeutics (DE:UTH) stock is held by public companies and individual investors.
Who owns the most shares of United Therapeutics (DE:UTH)?
iShares owns the most shares of United Therapeutics (DE:UTH).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.